Benralizumab fails to cut COPD exacerbations in phase 3 trials

  • Criner GJ & al.
  • N Engl J Med
  • 12 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Add-on benralizumab, an interleukin-5 receptor α-directed cytolytic monoclonal antibody, failed to prevent COPD exacerbations in the GALATHEA and TERRANOVA phase 3 randomised placebo-controlled trials.

Study design

  • GALATHEA (n=1120) and TERRANOVA (n=1545) were 56-week studies of add-on benralizumab vs placebo in patients with moderate to severe COPD and frequent exacerbations despite receiving guideline-based inhaled treatment.
  • Primary outcome: annualised COPD exacerbation rate ratio (RR) at week 56 in patients with baseline blood eosinophil counts ≥220/mm3.
  • Funding: AstraZeneca; Kyowa Hakko Kirin.

Key results

  • GALATHEA:
    • No differences between treatment vs placebo groups in the primary outcome:
      • Benralizumab 30 mg: RR, 0.96; 95% CI, 0.80-1.15.
      • Benralizumab 100 mg: RR, 0.83; 95% CI, 0.69-1.00.
  • TERRANOVA:
    • No differences between treatment vs placebo groups in the primary outcome:
      • Benralizumab 10 mg: RR, 0.85; 95% CI, 0.71-1.01.
      • Benralizumab 30 mg: RR, 1.04; 95% CI, 0.88-1.23.
      • Benralizumab 100 mg: RR, 0.93; 95% CI, 0.78-1.10.
  • No differences in adverse events between treatment and placebo groups in both trials.

Limitations

  • Study failed to account for an effect of baseline treatment type (e.g., systemic glucocorticoids and/or antibiotics) on benralizumab response.